The role of inflammatory cytokines in chemoresistance of epithelial ovarian cancer

doi:10.3760/cma.j.cn371439-20191010-00012

Abstract

Abstract:

Ovarian cancer is a common fatal malignant tumor in women. The most common pathological type is epithelial ovarian cancer (EOC) originating from the ovary or fallopian tube epithelium, accounting for 85%-90%. The standard treatment for EOC is tumor cytoreductive surgery. Postoperative platinum/paclitaxel chemotherapy, cell chemoresistance has become an important cause of recurrence and death in EOC patients. At present, many scholars believe that the tumor environment of ovarian cancer is rich in a broad spectrum of tumor pro-inflammatory cytokines and chemokines. Inflammation can increase the division and differentiation of epithelial cells. The long-term exposure of normal epithelial tissues to the inflammatory environment will gradually turn to malignant transformation. The inflammatory tumor microenvironment promotes the invasion and metastasis of transformed malignant tumor cells, and eventually develops drug resistance.

Key words: Ovarian neoplasms, Reactive oxygen species, Interleukin-6, Interleukin-8, Lysophospholipids

Yang Yiting, Cheng Zhongping. The role of inflammatory cytokines in chemoresistance of epithelial ovarian cancer[J]. Journal of International Oncology, 2020, 47(4): 249-251.

References 24

[1]	Savant SS, Sriramkumar S, O'Hagan HM. The Role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer[J]. Cancers (Basel), 2018, 10(8). pii: E251. DOI: 10.3390/cancers10080251.
[2]	Xuan Y, Wang YN . Hypoxia/IL-1α axis promotes gastric cancer progression and drug resistance[J]. J Dig Dis, 2017,18(9):511-520. DOI: 10.1111/1751-2980.12496. doi: 10.1111/cdd.2017.18.issue-9
[3]	Yu Y, Zhang Q, Ma C , et al. Mesenchymal stem cells recruited by castration-induced inflammation activation accelerate prostate cancer hormone resistance via chemokine ligand 5 secretion[J]. Stem Cell Res Ther, 2018,9(1):242. DOI: 10.1186/s13287-018-0989-8. doi: 10.1186/s13287-018-0989-8
[4]	李研 . 白藜芦醇对卵巢癌细胞顺铂化疗的增敏作用[J]. 国际肿瘤学杂志, 2018,45(1):5-9. DOI: 10.3760/cma.j.issn.1673-422X.2018.01.002.
[5]	Vaidyanathan A, Sawers L, Gannon AL , et al. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells[J]. Br J Cancer, 2016,115(4):431-441. DOI: 10.1038/bjc.2016.203. doi: 10.1038/bjc.2016.203
[6]	Kenda Suster N, Smrkolj S, Virant-Klun I . Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers[J]. J Ovarian Res, 2017,10(1):11. DOI: 10.1186/s13048-017-0306-7. doi: 10.1186/s13048-017-0306-7
[7]	Ricci F, Carrassa L, Christodoulou MS , et al. A high-throughput screening of a chemical compound library in ovarian cancer stem cells[J]. Comb Chem High Throughput Screen, 2018,21(1):50-56. DOI: 10.2174/1386207321666180124093406. doi: 10.2174/1386207321666180124093406
[8]	Cohen S, Mehrabi S, Yao X , et al. Reactive oxygen species and serous epithelial ovarian adenocarcinoma[J]. Cancer Res J (N Y N Y), 2016,4(6):106-114. DOI: 10.11648/j.crj.20160406.13.
[9]	Nunes SC, Serpa J. Glutathione in ovarian cancer: a double-edged sword[J]. Int J Mol Sci, 2018, 19(7). pii: E1882. DOI: 10.3390/ijms19071882.
[10]	Bansal A, Simon MC . Glutathione metabolism in cancer progression and treatment resistance[J]. J Cell Biol, 2018,217(7):2291-2298. DOI: 10.1083/jcb.201804161. doi: 10.1083/jcb.201804161
[11]	Browning L, Patel MR, Horvath EB , et al. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis[J]. Cancer Manag Res, 2018,10:6685-6693. DOI: 10.2147/CMAR.S179189. doi: 10.2147/CMAR
[12]	Wang L, Zhang F, Cui JY , et al. CAFs enhance paclitaxel resistance by inducing EMT through the IL6/JAK2/STAT3 pathway[J]. Oncol Rep, 2018,39(5):2081-2090. DOI: 10.3892/or.2018.6311.
[13]	Pasquier J, Gosset M, Geyl C , et al. CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer[J]. Mol Cancer, 2018,17(1):47. DOI: 10.1186/s12943-018-0787-z. doi: 10.1186/s12943-018-0787-z
[14]	Devapatla B, Sharma A, Woo S . CXCR2 inhibition combined with sorafenib improved antitumor and antiangiogenic response in preclinical models of ovarian cancer[J]. PLoS One, 2015,10(9):e0139237. DOI: 10.1371/journal.pone.0139237. doi: 10.1371/journal.pone.0139237
[15]	Wen J, Zhao Z, Huang L , et al. IL-8 promotes cell migration through regulating EMT by activating the Wnt/beta-catenin pathway in ovarian cancer[J]. J Cell Mol Med, 2020,24(2):1588-1598. DOI: 10.1111/jcmm.14848. doi: 10.1111/jcmm.v24.2
[16]	Li L, Yu J, Duan Z , et al. The effect of NFATc1 on vascular generation and the possible underlying mechanism in epithelial ovarian carcinoma[J]. Int J Oncol, 2016,48(4):1457-1466. DOI: 10.3892/ijo.2016.3355. doi: 10.3892/ijo.2016.3355
[17]	Cheng M, Cai W, Huang W , et al. Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription[J]. Eur J Pharmacol, 2018,840:1-8. DOI: 10.1016/j.ejphar.2018.09.032. doi: 10.1016/j.ejphar.2018.09.032
[18]	Stronach EA, Cunnea P, Turner C , et al. The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma[J]. Oncotarget, 2015,6(31):31593-31603. DOI: 10.18632/oncotarget.3415. doi: 10.18632/oncotarget.v6i31
[19]	Yin J, Zeng F, Wu N , et al. Interleukin-8 promotes human ovarian cancer cell migration by epithelial-mesenchymal transition induction in vitro[J]. Clin Transl Oncol, 2015,17(5):365-370. DOI: 10.1007/s12094-014-1240-4. doi: 10.1007/s12094-014-1240-4
[20]	Suckau O, Gross I, Schrötter S , et al. LPA₁, LPA₂, LPA₄, and LPA₆ receptor expression during mouse brain development[J]. Dev Dyn, 2019,248(5):375-395. DOI: 10.1002/dvdy.23. doi: 10.1002/dvdy.v248.5
[21]	Xu Y. Lysophospholipid signaling in the epithelial ovarian cancer tumor microenvironment[J]. Cancers (Basel), 2018, 10(7). pii: E227. DOI: 10.3390/cancers10070227.
[22]	Ray U, Roy SS, Chowdhury SR . Lysophosphatidic acid promotes epithelial to mesenchymal transition in ovarian cancer cells by repressing SIRT1[J]. Cell Physiol Biochem, 2017,41(2):795-805. DOI: 10.1159/000458744. doi: 10.1159/000458744
[23]	Rogers LC, Davis RR, Said N , et al. Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy[J]. Redox Biol, 2018,15:380-386. DOI: 10.1016/j.redox.2018.01.002. doi: 10.1016/j.redox.2018.01.002
[24]	Seo EJ, Kwon YW, Jang IH , et al. Autotaxin regulates maintenance of ovarian cancer stem cells through lysophosphatidic acid-mediated autocrine mechanism[J]. Stem Cells, 2016,34(3):551-564. DOI: 10.1002/stem.2279. doi: 10.1002/stem.2279